This comes after AIIMS’s Ethics Committee gave its nod for a human clinical trial of Covaxin on Saturday. The All India Institute of Medical Sciences [AIIMS] in Delhi will start enrolling healthy individuals from Monday for conducting the human clinical trial of Covaxin, the indigenously developed COVID 19-2020 vaccine candidate.
AIIMS Delhi is among the 23 institutes selected by the Indian Council for Medical Research [ICMR] for conducting phase I and II human trials of Covaxin. The vaccine would be tested on 775 volunteers during phase I and the maximum of 300 of them would be from AIIMS.
Mumbai Govt Announcement:-
We are launching the enrollment process from Monday. We are going to select healthy participants with no comorbidities and without a history of COVID 19-2020 Dr. Sanjay Rai, a professor at All India institute of medical science [AIIMS] Centre for Community Medicine, said, according to News Reports.
Now, Kejriwal taking lots of initiative for the management of the Covid19 Pandemic. He is the first chief minister who gave more importance to plasma Therapy for Coronavirus affected people in Delhi. As per doctor and clinical trial, it is reported that plasma therapy really impacts on COVID patients.
The age group of the study population is 18 to 55 years. This would be a randomized, double-blind, placebo-controlled clinical trial,” he said. He said that in the first and second phase All India institute of medical science [AIIMS] Delhi will choose only 370 participants out of 875 volunteers and the remaining will participate at other sites.
“We have already registered a few volunteers for the trial. From Monday onwards, our team will start their health screening before giving them vaccination,” he said. Covaxin, India’s first potential indigenous Covid-19 vaccine, has been jointly developed by the Indian Council of Medical Research [ICMR] and Bharat Biotech International Limited .
Also Read: Delhi’s Arvind Kejriwal on COVID 19
Hyderabad-based Bharat Biotech is among the seven Indian firms working on Covid-19 vaccines. It was the first to get the regulatory nod to begin phase 1 and phase 2 human trials to test the vaccine for efficacy and safety.
Bharat Biotech said in a statement on Friday that this is a randomized, double-blind placebo-controlled clinical trial with 375 volunteers. Bharat Biotech has said that human trials of Covaxin started on June 17th.
“Eventually, we plan to enroll 3,195 for both phases I and II. The human clinical trials commenced at AIIMS, Patna,” the statement by express himself. Zydus Cadila has also got an approval from the Drugs Controller General of India [DCGI] Cov-D, its indigenously developed vaccine candidates against causes COVID 19-20.